In 2017, while working as a researcher and lab manager at her alma mater, the University of Washington in Seattle, Allisa Song came across an article that stated drug companies were purposefully making eye drops too big, forcing consumers to constantly restock and buy more of their products.
Through further research, Song learned the human eye can only absorb between seven to 10 microliters of fluid, though companies were selling medications that dispense droplets between 35 and 70 microliters.
"There's this mismatch that existed between physiology and what was available," Song said. "It wouldn't be a really big deal if these medications only cost a couple of dollars."
Medication for glaucoma and other chronic eye conditions can cost hundreds of dollars per month, even with insurance, Song said.
Intrigued by the article — and motivated to soften the financial burden for individuals in need of eye medication — Song partnered with other recent graduates from the university and started a company that would develop a device that reduces the size of eye droplets by 60%.
That company, now headquartered in Rochester, has nearly 100 clinical partner locations across 24 states, including one in Lakeville, where patients are being supplied with its device called the Nanodropper.
Nanodropper Inc., the name of the company, charges $14.99 for the product, which can also be purchased on the company's website. To use, a person screws the device, which acts as an adapter, to the top of an eye liquid bottle. The device comes pre-assembled and sanitized.
Song did not disclose the company's revenue but said the device is being used by thousands of eye patients.